Gastric cancer
Therapeutic area
Gastroenterology
Rare disease
No
- Definition
- A primary or metastatic malignant neoplasm involving the stomach.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Gastric cancer
- Therapeutic area
- Gastroenterology
- gastric cancer
- gastric neoplasm
- Ca lesser curvature - stomach
- GC
- cancer of stomach
- gastric cancer
- gastric cancer risk after h. pylori infection
- gastric cancer, somatic
- malignant gastric neoplasm
- malignant gastric tumor
- malignant gastric tumour
- malignant neoplasm of lesser curve of stomach
- malignant neoplasm of stomach
- malignant neoplasm of the stomach
- malignant stomach neoplasm
- malignant tumor of body of stomach
- malignant tumor of greater curve of stomach
- malignant tumor of lesser curve of stomach
- malignant tumor of stomach
- malignant tumor of the stomach
- malignant tumour of body of stomach
- malignant tumour of greater curve of stomach
- malignant tumour of lesser curve of stomach
- malignant tumour of stomach
- malignant tumour of the stomach
And 4 more, listed on the interactive page.
- Severity
- Severe
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0001056
- Parent condition
- MONDO:0002516
Related records
Broader conditions (13)
- Cancer
- Cancer or benign tumor
- Digestive system cancer
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Gastric neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Stomach disorder
Narrower conditions (43)
- Carcinoma in situ of fundus of stomach
- Carcinoma in situ of gastric body
- Carcinoma in situ of gastric cardia
- Carcinoma of stomach, salivary gland type
- Cardia cancer
- CTNNA1-related diffuse gastric and lobular breast cancer syndrome
- Diffuse gastric adenocarcinoma
- Diffuse gastric cancer
- Epstein-Barr virus-associated gastric carcinoma
- Gastric adenocarcinoma
- Gastric adenocarcinoma and proximal polyposis of the stomach
- Gastric adenosquamous carcinoma
- Gastric body carcinoma
- Gastric carcinoma
- Gastric cardia adenocarcinoma
- Gastric cardia carcinoma
- Gastric choriocarcinoma
- Gastric fundus carcinoma
- Gastric intestinal type adenocarcinoma
- Gastric leiomyosarcoma
Trials (2,217)
- "Mechanisms and Biomarkers of Response and Resistance to Current Targeted Therapies in Gastric Cancer" (THERRES)
- "Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy
- "The Impact of Immunonutrition on Gut Microbiota-related Aspects in Colorectal Cancer and Gastric Cancer Patients"
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer
- 124I-FIAU Imaging in EBV and KSHV Associated Cancers
- 18F-FAPI PET/CT and MRI in Gastric Cancer
- 18F-FDG PET/CT in Gastric Cancer
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
- 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
- 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A Benefit Population Atlas of nICT Versus nCT for LAGC
Approved drugs (5)
Drugs in development (189)
- 9-aminocamptothecin Phase 2
- Adebrelimab Phase 2
- Albumin human Phase 3
- Alofanib Phase 1
- Alpelisib Phase 1
- Amivantamab Phase 2
- Ascorbic acid Phase 3
- Aspirin Phase 3
- Atezolizumab Phase 2
- Avelumab Phase 3
- Axitinib Phase 1
- AZD-1480 Phase 1
- AZD-8186 Phase 1
- Bemarituzumab Phase 2
- Bevacizumab Phase 3
- Bintrafusp alfa Phase 1
- Bleomycin Phase 1
- BMS-986310 Phase 2
- Bortezomib Phase 2
- Bryostatin 1 Phase 2
Other linked drugs (10)
- Anamorelin hydrochloride
- Catequentinib hydrochloride
- Esomeprazole magnesium
- Evorpacept
- Leniolisib
- Mosapride citrate
- Satricabtagene autoleucel
- Tebentafusp
- Vonoprazan fumarate
- Zolbetuximab